secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001104659-22-004549
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts United Therapeutics' resubmitted NDA for Tyvaso DPI as Class 1 review; target date Feb 2022
--------------------------------------------------------------------------------

- FDA accepted resubmission of NDA for Tyvaso DPI as a Class 1 response after Complete Response Letter in Oct 2021.
- User fee goal date (PDUFA) set for February 2022, indicating expedited review.
- Tyvaso DPI is an inhaled treprostinil product for pulmonary arterial hypertension.
- Resubmission made on Dec 27, 2021, and accepted for review on Jan 18, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922004549/0001104659-22-004549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922004549/tm223084d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-004549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer